Pelthos Therapeutics Appoints New CFO and Discloses Governance Votes
Pelthos Therapeutics Inc. (SEC file no. 0001919246) filed an 8-K on October 1, 2026, announcing CFO appointment, director elections, and shareholder voting outcomes. The filing includes updated financial statements and executive compensation details.
51CFO view：CFO appointments at pre-IPO biotechs trigger SEC scrutiny of background verifiability, regulatory eligibility, and disclosure alignment in the 'Management' section. Candidates must hold USCPA, demonstrate FDA submission support experience, and have led financial reporting for ≥2 pre-IPO biotechs—critical for S-1 credibility.
Pelthos Therapeutics Inc. (SEC file no. 0001919246) filed an 8-K on October 1, 2026, announcing CFO appointment, director elections, and shareholder voting outcomes. The filing includes updated financial statements and executive compensation details.
Source：SEC EDGAR · 8-K 重大事项公告
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
How is a US-listed CFO paid?
Base, equity incentive and listing-milestone bonus: structure and ranges.
Read →
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →